In treating hematologic malignancies, engineered T-cell therapy outperforms standard transplantation with respect to chronic ...
highlighting potential disparities in cancer care. Hematological malignancies represent 6.5% of global cancer incidence, rising to 9.0% in the U.S. and Europe. Despite significant improvements in ...
GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.
The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...
Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, Ph.D., Ward-Coleman Chair in Cancer ...
The following is a summary of “Effect of radioactive iodine therapy on hematological parameters in patients with thyroid ...
According to a study published in JAMA Network Open, among patients with type 2 diabetes (T2D), the use of glucagon-like ...
No significant difference was seen in the risk for any other hematologic cancer. GLP-1 RA use was associated with significantly lower risks for myeloid leukemia, lymphoid leukemia, non-Hodgkin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback